Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:56:57 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:ALIM - ALIMERA SCIENCES INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ALIM - Q0.12.75·3.980.13.48+0.020.642.91303983.47  3.59  3.3354.38  1.5616:00:01Apr 3015 min RT 2¢

Recent Trades - Last 10 of 398
Time ETExPriceChangeVolume
16:00:01Q3.480.0264
16:00:01Q3.480.0224
16:00:01Q3.480.0217
16:00:01Q3.480.025
16:00:01Q3.480.0217
16:00:01Q3.480.0216
16:00:01Q3.480.0216
16:00:01Q3.480.0222
16:00:01Q3.480.0229
16:00:01Q3.480.02100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-30 08:00U:ALIMNews ReleaseAlimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
2024-03-20 08:00U:ALIMNews ReleaseAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 08:00U:ALIMNews ReleaseAlimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
2024-03-07 07:30U:ALIMNews ReleaseAlimera Sciences Reports Fourth Quarter and Full Year 2023 Results
2024-02-29 08:00U:ALIMNews ReleaseAlimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
2024-02-08 08:00U:ALIMNews ReleaseThe UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN ‚ ®
2024-01-04 08:00U:ALIMNews ReleaseAlimera Completes Recruitment for the Synchronicity Study
2024-01-02 08:00U:ALIMNews ReleaseAlimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-12-12 07:30U:ALIMNews ReleaseAlimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-08 16:30U:ALIMNews ReleaseAlimera Appoints Maggie A. Pax to Its Board of Directors
2023-10-31 08:00U:ALIMNews ReleaseAlimera Announces Scientific Data Highlighting ILUVIEN ‚ ® To Be Presented at the American Academy of Ophthalmology
2023-10-26 07:00U:ALIMNews ReleaseAlimera Sciences Reports Third Quarter 2023 Results
2023-10-16 08:00U:ALIMNews ReleaseAlimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update
2023-10-11 08:00U:ALIMNews ReleaseAlimera Announces Multiple Presentations Highlighting ILUVIEN ‚ ® and YUTIQ ‚ ® Data at Retina Society Annual Congress
2023-10-03 08:00U:ALIMNews ReleaseAlimera Sciences Appoints Jason Werner as Chief Operating Officer
2023-09-05 08:00U:ALIMNews ReleaseAlimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-10 07:30U:ALIMNews ReleaseAlimera Sciences Reports Second Quarter 2023 Results
2023-08-08 09:16U:ALIMNews ReleaseStonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
2023-08-02 11:44U:ALIMNews ReleaseAlimera Sciences to Report Second Quarter 2023 Financial Results ‚  on August 10, 2023, and Provide Corporate Update
2023-05-24 08:00U:ALIMNews ReleaseAlimera Completes Recruitment for its Landmark NEW DAY Study